Apolizumab
As of the edition of 20 October 2026, Apolizumab is an antibody: stopped in 2017; acts on HLA-DRB1, HLA-DRB3 and HLA-DRB4 and 1 more.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Stopped, 2017
- Kind
- Antibody
- Registered trials
- 6, 1 stopped early
- Disease areas
- Blood and lymph; Cancer; Immune system; Infections
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 3 | 2 | 0 | 1 |
| Phase 2 | 3 | 2 | 0 | 0 |
| All trials | 6 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| PDL BioPharma | Lead sponsor of trials | 2000 to now |